文献速递肾小球疾病肾移植

新型体外实验检测特发性局灶节段性肾小球硬化中的循环通透性因子

Novel in vitro assays to detect circulating permeability factor(s) in idiopathic focal segmental glomerulosclerosis.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

该研究开发了基于人足细胞和肾小球内皮细胞的体外实验,用于检测特发性FSGS患者血浆中的循环通透性因子(CPF)。活动期血浆可诱导足细胞颗粒化,缓解期和健康血浆则无或较弱,且胎牛血清、健康血浆和缓解期血浆可部分阻断该效应。结果表明CPF与CPF抑制因子之间存在平衡,该实验有望用于识别CPF及预测肾移植后复发。

要点

  • 活动期FSGS血浆可诱导人足细胞颗粒化,呈剂量和时间依赖性。
  • 缓解期和健康血浆颗粒化诱导作用弱或无,且可部分阻断活动期血浆效应。
  • 该体外实验可用于CPF及CPF抑制因子的识别和移植后复发预测研究。

核心结论

  • 活动期FSGS血浆可诱导培养人足细胞颗粒化,提示存在CPF,且健康与缓解期血浆可能含CPF抑制因子。

研究设计与样本

  • 体外实验:将人足细胞、人肾小球内皮细胞和小鼠肾小球内皮细胞暴露于10例推测含CPF的FSGS患者血浆及疾病对照血浆。

主要发现

  • 13份活动期血浆中9份诱导人足细胞颗粒化,呈剂量和时间依赖性。
  • 对应缓解期血浆诱导人足细胞颗粒化无或较少。
  • 人及小鼠肾小球内皮细胞结果类似,但颗粒化程度低于人足细胞。
  • 胎牛血清、健康血浆和缓解期血浆可部分阻断FSGS血浆诱导的人足细胞颗粒化。

临床怎么用

  • 该实验可用于未来研究识别CPF和CPF抑制因子,并可能用于预测肾移植后复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many patients with idiopathic focal segmental glomerulosclerosis (FSGS) develop recurrence of proteinuria after kidney transplantation (TX). Although several circulating permeability factors (CPFs) responsible for recurrence have been suggested, there is no consensus. To facilitate CPF identification and predict recurrence after TX, there is a need for robust methods that demonstrate the presence of CPFs. METHODS: Cultured human podocytes (hPods) and human and mouse glomerular endothelial cells (ciGEnC, mGEnC) were exposed to plasmas of FSGS patients with presumed CPFs, and of (disease) controls. A visual scoring assay and flow cytometry analysis of side scatter were used to measured changes in cellular granularity after exposure to plasma. RESULTS: Nine out of 13 active disease plasmas of 10 FSGS patients with presumed CPFs induced granularity in hPod in a dose- and time-dependent manner. Corresponding remission plasmas induced no or less granularity in hPod. Similar results were obtained with ciGEnC and mGEnC, although induced granularity was less compared with hPod. Notably, foetal calf serum, healthy plasma and a remission plasma partially blocked FSGS plasma-induced hPod granularity. CONCLUSIONS: We developed a novel assay in which active disease, presumably CPF-containing, FSGS plasmas induced granularity in cultured hPod. Our results may indicate the presence of CPF inhibitor(s) in healthy and remission plasma. We suggest the presence of a delicate balance between CPF and a CPF inhibitory factor, which is disturbed in patients with active disease. Our novel assays can be applied in future research to identify CPF and CPF inhibitors, and possibly to predict recurrence after TX.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. den Braanker DJW, Maas RJ, Deegens JK, et al. Novel in vitro assays to detect circulating permeability factor(s) in idiopathic focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2021. PMID: 33155059. doi:10.1093/ndt/gfaa211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。